Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer

Julia McAdams,Jasmine Ebott,Corinne Jansen,Chloe Kim,Daniela Maiz,Joyce Ou,Linda C. Hanley,Payton De La Cruz,Nicole E. James
DOI: https://doi.org/10.1186/s13048-024-01516-y
2024-09-30
Journal of Ovarian Research
Abstract:High grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy in which patients have still yet to respond meaningfully to clinically available immunotherapies. Hence, novel immune targets are urgently needed. Our past work has identified that mast cells are significantly upregulated at the mRNA level in HGSOC patient tumors following neoadjuvant chemotherapy (NACT) exposure. Therefore, in this current investigation we sought to characterize intratumoral mast cell phenotypic changes as a result of NACT exposure and determine how these adaptations are associated with patient clinical outcomes.
reproductive biology
What problem does this paper attempt to address?